Overall verdict
Neutral
5.7/10
1-year performance
-9.88%
Score breakdown
Down 9.9% over 1 year, 38% of the 52-week range.
Strongest: Valuation 10.0/10. Weakest: Growth 2.3/10.
7 analysts, target -0.4% vs the price.
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics ; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence ;
and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products.
In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Xetr
Germany
CEO
Ms. Helen Giza
Founded
1996
Employees
111 024
Revenue / employee
181 896 EUR
Next earnings
November 3, 2026 (Q3 2026)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
47.86 EUR
52-week low
34.57 EUR
1-year performance
-9.88%
Declining
Year-to-date performance
-3.43%
Declining
Drawdown
-17.09%
Marked drawdown
Position in the 52-week range
38% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did clearly worse than the world ETF once risk is accounted for. It earned less, while shaking 2.0 times harder.
10,000 € placed at the end of September 2009 are worth today
| Fresenius Medical | 11 593 € |
| World ETF | 74 620 € |
| STOXX Europe 600 | 39 543 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 2.0 times as much as the world ETF.
- Worst fall:-72 % between January 2018 and October 2022. 10,000 € placed at the top fell to 2 824 €. The world ETF, at worst: -34 %. The share has not returned to its high yet.
Fresenius Medical earned less than the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Fresenius Medical: 11 593 €
- World ETF: 74 620 €
- STOXX Europe 600: 39 543 €
- Risk-free placement: 11 288 €
Share price without dividends; the world ETF and the index reinvest theirs. A dividend payer is therefore understated here.
Based on past performance. This is not a recommendation.
Range: 104.32 EUR - 128.59 EUR (2 methods agree)
The price implies growth of -11.54% per year; the company grows at -3.22%.
Gross margin 26.4%, net margin 4.8%, ROIC 4.3%, ROE 7.3%.
Net margin
4.83%
Exceptional
Sector 3.21%|S&P 12.97%
Gross margin
26.36%
Fair
Return on equity (ROE)
7.26%
Fair
Sector 6.71%|S&P 16.52%
Return on invested capital (ROIC)
4.27%
Fair
Free cash flow margin (FCF)
9.19%
High
Profit-to-cash conversion (FCF conversion)
1.90x
High
Margin stability
2.6 pts
Steady
Revenue to net income
Growth
2.3/10Revenue up 1.4% over 1 year, 1.9% a year over 5, EPS -3.2% a year over 5.
Revenue (trailing 12 months)
19.6Md EUR
Revenue growth (1y)
1.44%
Moderate
Revenue growth (3y)
1.25%
Moderate
EPS growth (1y)
5.95%
Moderate
EPS CAGR (5y)
-3.22%
Declining
EPS revisions (3 months)
3.01%
Revised up
Valuation
10.0/10P/E 11.9x, forward P/E 13.7x, EV/EBITDA 6.0x, PEG 0.24. The multiple sits in the 18th percentile of its own 5-year history.
P/E (TTM)
11.9x
Cheap
Sector 30.9x|S&P 23.0x
Forward P/E
13.7x
Cheap
EV / EBITDA
6.0x
Cheap
Sector 13.1x|S&P 14.5x
PEG
0.24
Growth unpriced
Sector 0.75|S&P 0.86
Fair value (reverse DCF)
116.45 EUR
Deeply undervalued
P/E vs its own 5-year history
among the 18% lowest valuations
Far cheaper than usual
Market cap
10.5Md EUR
Financial strength
3.8/10Cash covers 9.7% of the debt, net debt/EBITDA 2.7x.
Net debt / EBITDA
2.7x
Tight
Gearing (net debt / equity)
73.18%
Tight
Cash
1.0Md EUR
Cash / market cap
9.80%
Solid
Cash / total debt
9.68%
Stretched
Interest coverage
5.1x
Solid
Net debt
9.6Md EUR
Equity
13.2Md EUR
Closed daily candles, 2 years
Last close on September 24, 2026: 39.35 EUR
- MM2039.19
- MM5040.87
- MM20039.65
- RSI 1446.7
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-0.37%
200-day average slope, 3 months
-1.94%
50-day average slope, 1 month
-2.15%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.20 % per day
Volatility change
-29.34%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 2.90 (10) | 4.05 (14) | 19 556 (17) | 3 489 (13) | 801 (10) |
| 2027 | 3.96 (11) | 4.34 (15) | 20 219 (16) | 3 666 (14) | 1 028 (10) |
Amounts in millions of EUR, EPS in EUR per share. In brackets, the number of analysts. Consensus as of September 18, 2026.
Same sub-industry: 77 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | HNGE | 7.2 | 6.6 | 7.4Md USD | 71.1x | 14.8 % | 53.0 % | 29.3 % | -3.8x | 3.8 % | 55.7 % | ||
| 2 | CI | 7.0 | 7.1 | 70.9Md USD | 11.1x | 2.3 % | 6.5 % | 9.3 % | 1.8x | 12.9 % | -8.0 % | ||
| 3 | LH | 6.7 | 5.9 | 24.7Md USD | 25.1x | 7.0 % | 5.8 % | 6.8 % | 2.4x | 4.7 % | 10.4 % | ||
| 4 | CVS | 6.6 | 5.9 | 110Md USD | 22.7x | 1.2 % | 7.2 % | 3.2 % | 4.1x | 10.7 % | 10.9 % | ||
| 5 | DVA | 6.5 | 6.4 | 11.7Md USD | 15.4x | 5.9 % | 5.2 % | 6.9 % | 4.5x | 13.8 % | 32.3 % | ||
| 6 | DGX | 6.5 | 5.8 | 25.7Md USD | 24.7x | 9.2 % | 10.2 % | 7.9 % | 2.8x | 5.2 % | 26.9 % | ||
| 7 | BTSG | 6.4 | 4.9 | 11.0Md USD | 41.7x | 1.7 % | 23.0 % | 5.7 % | 4.6x | 3.6 % | 102.1 % | ||
| 8 | FME | 5.7 | 6.6 | 12.0Md USD | 11.9x | 4.8 % | 1.4 % | 4.3 % | 2.7x | 17.0 % | -9.9 % | ||
| 9 | GH | 4.7 | 2.6 | 23.7Md USD | Not meaningful (loss) | -38.3 % | 44.3 % | -37.0 % | -1.5x | -1.0 % | 189.0 % |
